Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 7/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8288621 | 1.00 | HSD17B10 (0.37) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL8285616 | 0.88 | HSD17B10 (0.37) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL5495474 | 0.85 | PTPN1 (0.34) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL5379806 | 0.85 | PTPN1 (0.34) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL883020 | 0.83 | HSD17B10 (0.38) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL8290352 | 0.83 | — | — | |
| SCHEMBL22320894 | 0.83 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL8288622 | 0.81 | SPHK1 (0.35) | SMN1; SMN2 | |
| SCHEMBL27207278 | 0.81 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL27203890 | 0.81 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7179918-B2 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179918-B2 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179918-B2 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-20070021354-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | CANAN KOCH STACIE S | 2007-01-25 | — | — | US | disclosed |
| US-20070021354-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | CANAN KOCH STACIE S | 2007-01-25 | — | — | US | disclosed |
| US-20070021354-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | CANAN KOCH STACIE S | 2007-01-25 | — | — | US | disclosed |
| EP-1737818-A2 | METHODS FOR THE PREPARATION OF STEREOISOMERICALLY ENRICHED AMINES | Pfizer, Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1713470-A1 | THERAPEUTIC COMBINATIONS | Pfizer, Inc. (US) | 2006-10-25 | — | — | EP | disclosed |
| EP-1713478-A1 | COMPOSITIONS COMPRISING HIV PROTEASE INHIBITOR AND CYTOCHROME P450 ENZYME ACTIVITY INHIBITOR | PFIZER INC. (US) | 2006-10-25 | — | — | EP | disclosed |
| EP-1692104-A1 | METHODS OF PREPARING COMPOUNDS USEFUL AS PROTEASE INHIBITORS | PFIZER INC. (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050153903-A1 | Methods of preparing compounds useful as protease inhibitors | AGOURON PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| WO-2005054186-A2 | METHODS FOR THE PREPARATION OF STEREOISOMERICALLY ENRICHED AMINES | PFIZER INC. (US) | 2005-06-16 | — | — | WO | disclosed |
| WO-2005054187-A1 | METHODS OF PREPARING COMPOUNDS USEFUL AS PROTEASE INHIBITORS | PFIZER INC. (US) | 2005-06-16 | — | — | WO | disclosed |
| WO-2005054187-A1 | METHODS OF PREPARING COMPOUNDS USEFUL AS PROTEASE INHIBITORS | PFIZER INC. (US) | 2005-06-16 | — | — | WO | disclosed |
| US-20050124683-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2005-06-09 | — | — | US | disclosed |
| WO-2005026114-A1 | HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME AND THEIR PHARMACEUTICAL USES | PFIZER INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20040204591-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2004-10-14 | — | — | US | disclosed |
| EP-1409466-A2 | HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME, THEIR PHARMACEUTICAL USES AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030225071-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | PFIZER INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2002100844-A2 | HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME, THEIR PHARMACEUTICAL USES AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021354-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | SERPINB1, PEPD, PREP | HSD17B10 962/4885SMN1; SMN2 3932/4885CHRM2 4867/4885 |
| US-20050153903-A1 | Methods of preparing compounds useful as protease inhibitors | PREP, FURIN, SERPINB1 | HSD17B10 711/4885SMN1; SMN2 3397/4885CHRM2 4795/4885 |
| US-20030225071-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | SERPINB1, FURIN, PEPD | HSD17B10 1113/4885SMN1; SMN2 3798/4885CHRM2 4853/4885 |
| US-20050124683-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | PEPD, SERPINB1, ACE | HSD17B10 2330/4885SMN1; SMN2 4320/4885CHRM2 4869/4885 |
| US-20040204591-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | FURIN, PREP, PRSS1 | HSD17B10 439/4885SMN1; SMN2 3614/4885CHRM2 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.